脂浊宁治疗痰浊阻遏型高脂血症的临床研究

Clinical Study of Zhizhuoning in the Treatment of Hyperlipidemia of Phlegm-Turbidity Obstruction Type

摘要:

目的：观察脂浊宁治疗痰浊阻遏型高脂血症的临床疗效及安全性。方法：选取2024年11月1日—2025年11月30日于广州中医药大学东莞医院就诊且符合诊断标准的高脂血症患者102例，采用随机数字表法分为试验组和对照组，各51例。对照组口服血脂康胶囊，试验组口服脂浊宁，疗程均为8周。观察2组治疗前后血脂指标、中医症状积分及安全性指标的变化，评价临床疗效及安全性。结果：2组治疗前基线资料均衡可比。治疗后2组总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C） 及中医症状积分较治疗前均有不同程度的改善（P＜0.05）；治疗后试验组TC 水平低于对照组，且TC、LDL-C 下降幅度大于对照组（P＜0.05）；治疗后试验组主要症状积分、次要症状积分下降幅度亦大于对照组（P＜0.05）；试验组总有效率为90.20%，高于对照组的72.55%；治疗期间2组均未见明显不良反应。结论：脂浊宁可改善痰浊阻遏型高脂血症患者的血脂水平和中医证候表现，在降低TC、LDL-C及改善临床症状方面具有一定优势，短期应用安全性较好。

Abstract:

Abstract： Objective： To observe the clinical efficacy and safety of Zhizhuoning in the treatment of hyperlipidemia of phlegm-turbidity obstruction type. Methods：A total of 102 patients with hyperlipidemia who met the diagnostic criteria and visited Dongguan Hospital of Guangzhou Universaity of Chinese Medicine from November 1， 2024，to November 30，2025，were enrolled. They were randomly divided into a trial group and a control group using a random number table method，with 51 cases in each group. The control group received Xuezhikang Capsules，while the trial group received oral administration of Zhizhuoning， both for a course of eight weeks. Changes in blood lipid parameters， traditional Chinese medicine symptom scores， and safety indicators were observed before and after treatment in both groups， and the clinical efficacy and safety were evaluated. Results： The baseline data of the two groups were balanced and comparable before treatment. After treatment， total cholesterol （TC）， triglyceride （TG）， low-density lipoprotein cholesterol （LDL-C）， and traditional Chinese medicine symptom scores in both groups improved to varying degrees compared with those before treatment （P＜0.05）. After treatment，the TC level in the trial group was lower than that in the control group， and the reductions in TC and LDL-C levels were greater in the trial group than in the control group （P＜0.05）. The decreases in primary and secondary symptom scores in the trial group were also greater than those in the control group （P＜0.05）. The total effective rate in the trial group was 90.20%， which was higher than the 72.55% in the control group. No significant adverse reactions were observed in either group during treatment. Conclusion：Zhizhuoning can improve blood lipid levels and traditional Chinese medicine syndrome manifestations in patients with hyperlipidemia of phlegm-turbidity obstruction type. It shows certain advantages in lowering TC and LDL-C levels and alleviating clinical symptoms，and exhibites good short-term safety.